{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T04:06:38Z","timestamp":1776744398980,"version":"3.51.2"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"32","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2021,8,12]]},"abstract":"<jats:title><jats:bold>Abstract<\/jats:bold><\/jats:title><jats:p>Peritoneal metastasis is a common issue in the progression of high-grade serous ovarian cancers (HGSOCs), yet the underlying mechanism remains unconfirmed. We demonstrated that ZEB2, the transcription factor of epithelial\u2013mesenchymal transition (EMT), was upregulated in ascites cells from HGSOC patients and in CD133<jats:sup>+<\/jats:sup>cancer stem-like cells (CSLCs) from epithelial ovarian cancer (EOC) cell lines. SiRNA-mediated knockdown of ZEB2 in EOC cells decreased the percentage of CSLCs and reduced the colony forming potential, cell invasion capacity and expression of pluripotent genes Oct4 and Nanog. Inhibition of ZEB2 also induced cellular apoptosis and impacted the tumorigenicity of ovarian CSLCs. The mesenchymal markers N-cadherin and vimentin were downregulated, while the epithelial marker E-cadherin was upregulated after ZEB2 knockdown. MiR-200a, a molecule that downregulates ZEB2, had the opposite effect of ZEB2 expression in EOC-CSLCs. A retrospective study of 98 HGSOC patients on the relationship of ascites volume, pelvic and abdominal metastasis, International Federation of Gynecology and Obstetrics (FIGO) stage and the malignant involvement of abdominal organs and lymph nodes was performed. Patients with high expression of ZEB2 in tumour tissues had a higher metastasis rate and a poorer prognosis than those with low expression. The parameters of ZEB2 expression and ascites volume were strongly linked with the prognostic outcome of HGSOC patients and had higher hazard ratios. These findings illustrated that ZEB2 facilitates the invasive metastasis of EOC-CSLCs and can predict peritoneal metastasis and a poor prognosis in HGSOC patients.<\/jats:p>","DOI":"10.1038\/s41388-021-01913-3","type":"journal-article","created":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T19:04:55Z","timestamp":1625166295000},"page":"5131-5141","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["ZEB2 facilitates peritoneal metastasis by regulating the invasiveness and tumorigenesis of cancer stem-like cells in high-grade serous ovarian cancers"],"prefix":"10.1038","volume":"40","author":[{"given":"Yiying","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4686-4977","authenticated-orcid":false,"given":"He","family":"Fei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiwang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanan","family":"You","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengyao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengfei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7895-2077","authenticated-orcid":false,"given":"Tong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5235-341X","authenticated-orcid":false,"given":"Hua","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,1]]},"reference":[{"key":"1913_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7\u201330.","journal-title":"CA Cancer J Clin"},{"key":"1913_CR2","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1158\/0008-5472.CAN-18-2297","volume":"79","author":"J Hooda","year":"2019","unstructured":"Hooda J, Novak M, Salomon MP, Matsuba C, Ramos RI, MacDuffie E, et al. Early loss of histone H2B monoubiquitylation alters chromatin accessibility and activates key immune pathways that facilitate progression of ovarian cancer. Cancer Res. 2019;79:760\u201372.","journal-title":"Cancer Res"},{"key":"1913_CR3","doi-asserted-by":"publisher","first-page":"6145","DOI":"10.2147\/OTT.S209784","volume":"12","author":"T Zheng","year":"2019","unstructured":"Zheng T, Qiu J, Li C, Lin X, Tang X, Hua K. Long noncoding RNA LINC00673 promotes the proliferation and metastasis of epithelial ovarian cancer by associating with opioid growth factor receptor. Onco Targets Ther. 2019;12:6145\u201356.","journal-title":"Onco Targets Ther"},{"key":"1913_CR4","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3322\/caac.21456","volume":"68","author":"LA Torre","year":"2018","unstructured":"Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68:284\u201396.","journal-title":"CA Cancer J Clin"},{"key":"1913_CR5","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/onc.2016.197","volume":"36","author":"U Saini","year":"2017","unstructured":"Saini U, Naidu S, Elnaggar AC, Bid HK, Wallbillich JJ, Bixel K, et al. Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis a potential therapeutic target. Oncogene. 2017;36:168\u201381.","journal-title":"Oncogene."},{"key":"1913_CR6","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1111\/cas.12987","volume":"107","author":"S Kim","year":"2016","unstructured":"Kim S, Kim B, Song YS. Ascites modulates cancer cell behavior, contributing to tumor heterogeneity in ovarian cancer. Cancer Sci. 2016;107:1173\u20138.","journal-title":"Cancer Sci"},{"key":"1913_CR7","doi-asserted-by":"publisher","first-page":"3744","DOI":"10.1158\/0008-5472.CAN-11-2695","volume":"72","author":"TJ Webb","year":"2012","unstructured":"Webb TJ, Li X, Giuntoli RL II, Lopez PH, Heuser C, Schnaar RL, et al. Molecular identification of GD3 as a suppressor of the innate immune response in ovarian cancer. Cancer Res. 2012;72:3744\u201352.","journal-title":"Cancer Res"},{"key":"1913_CR8","unstructured":"Matte I, Lane D, Laplante C, Rancourt C, Pich\u00e9 A. Profiling of cytokines in human epithelial ovarian cancer ascites. Am J Cancer Res. 2012;2:566\u201380. http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=PMC3433103."},{"key":"1913_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-6321-x","volume":"19","author":"J Shi","year":"2019","unstructured":"Shi J, Huo R, Li N, Li H, Zhai T, Li H, et al. CYR61, a potential biomarker of tumor inflammatory response in epithelial ovarian cancer microenvironment of tumor progress. BMC Cancer. 2019;19:1140.","journal-title":"BMC Cancer"},{"key":"1913_CR10","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.4110\/in.2018.18.e29","volume":"18","author":"RMC Ignacio","year":"2018","unstructured":"Ignacio RMC, Lee E-S, Wilson AJ, Beeghly-Fadiel A, Whalen MM, Son D-S. Chemokine network and overall survival in TP53 wild-type and mutant ovarian cancer. Immune Netw. 2018;18:e29.","journal-title":"Immune Netw"},{"key":"1913_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14556-x","volume":"11","author":"AR Louren\u00e7o","year":"2020","unstructured":"Louren\u00e7o AR, Roukens MG, Seinstra D, Frederiks CL, Pals CE, Vervoort SJ, et al. C\/EBPa is crucial determinant of epithelial maintenance by preventing epithelial-to-mesenchymal transition. Nat Commun. 2020;11:785.","journal-title":"Nat Commun"},{"key":"1913_CR12","doi-asserted-by":"publisher","first-page":"eaay9819","DOI":"10.1126\/sciadv.aay9819","volume":"6","author":"Q Wu","year":"2020","unstructured":"Wu Q, Li G, Wen C, Zeng T, Fan Y, Liu C, et al. Monoubiquitination of p120-catenin is essential for TGFbeta-induced epithelial-mesenchymal transition and tumor metastasis. Sci Adv. 2020;6:eaay9819.","journal-title":"Sci Adv"},{"key":"1913_CR13","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.pharmthera.2018.09.007","volume":"194","author":"MK Jolly","year":"2019","unstructured":"Jolly MK, Somarelli JA, Sheth M, Biddle A, Tripathi SC, Armstrong AJ, et al. Hybrid epithelial\/mesenchymal phenotypes promote metastasis and therapy resistance across carcinomas. Pharm Ther. 2019;194:161\u201384.","journal-title":"Pharm Ther"},{"key":"1913_CR14","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/1878-0261.12017","volume":"11","author":"KT Yeung","year":"2017","unstructured":"Yeung KT, Yang J. Epithelial-mesenchymal transition in tumor metastasis. Mol Oncol. 2017;11:28\u201339.","journal-title":"Mol Oncol"},{"key":"1913_CR15","doi-asserted-by":"publisher","unstructured":"Tripathi S, Levine H, Jolly MK. The physics of cellular decision making during epithelial-mesenchymal transition. Annu Rev Biophys. 2020. https:\/\/doi.org\/10.1146\/annurev-biophys-121219-081557.","DOI":"10.1146\/annurev-biophys-121219-081557"},{"key":"1913_CR16","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41580-020-0237-9","volume":"21","author":"J Yang","year":"2020","unstructured":"Yang J, Antin P, Berx G, Blanpain C, Brabletz T, Bronner M, et al. Guidelines and definitions for research on epithelial\u2013mesenchymal transition. Nat Rev Mol Cell Biol. 2020;21:341\u2013352.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1913_CR17","doi-asserted-by":"publisher","unstructured":"Loret N, Denys H, Tummers P, Berx G. The role of epithelial-to-mesenchymal plasticity in ovarian cancer progression and therapy resistance. Cancers. 2019;11. https:\/\/doi.org\/10.3390\/cancers11060838.","DOI":"10.3390\/cancers11060838"},{"key":"1913_CR18","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.immuni.2018.07.004","volume":"49","author":"CL Scott","year":"2018","unstructured":"Scott CL, T'jonck W, Martens L, Todorov H, Sichien D, Soen B, et al. The transcription factor ZEB2 is required to maintain the tissue-specific identities of macrophages. Immunity. 2018;49:312\u201325.e5.","journal-title":"Immunity"},{"key":"1913_CR19","doi-asserted-by":"publisher","first-page":"7213","DOI":"10.1007\/s13277-015-3437-8","volume":"36","author":"C Liu","year":"2015","unstructured":"Liu C, Yang F. Akt2\/ZEB2 may be a biomarker for exfoliant cells in ascitic fluid in advanced grades of serous ovarian carcinoma. Tumour Biol. 2015;36:7213\u20139.","journal-title":"Tumour Biol"},{"key":"1913_CR20","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1159\/000438635","volume":"38","author":"N Song","year":"2016","unstructured":"Song N, Liu H, Ma X, Zhang S. Placental growth factor promotes ovarian cancer cell invasion via ZEB2. Cell Physiol Biochem. 2016;38:351\u20138.","journal-title":"Cell Physiol Biochem"},{"key":"1913_CR21","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.3390\/ijms18061207","volume":"18","author":"P-W Choi","year":"2017","unstructured":"Choi P-W, Ng S-W. The functions of MicroRNA-200 family in ovarian cancer: beyond epithelial-mesenchymal transition. Int J Mol Sci. 2017;18:1207.","journal-title":"Int J Mol Sci"},{"key":"1913_CR22","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1038\/nprot.2006.328","volume":"1","author":"TG Shepherd","year":"2006","unstructured":"Shepherd TG, Th\u00e9riault BL, Campbell EJ, Nachtigal MW. Primary culture of ovarian surface epithelial cells and ascites-derived ovarian cancer cells from patients. Nat Protoc. 2006;1:2643\u20139.","journal-title":"Nat Protoc"},{"key":"1913_CR23","doi-asserted-by":"publisher","first-page":"4570","DOI":"10.18632\/oncotarget.27827","volume":"11","author":"JE Den Ouden","year":"2020","unstructured":"Den Ouden JE, Zaman GJR, Dylus J, Van Doornmalen AM, Mulder WR, Grobben Y, et al. Chemotherapy sensitivity testing on ovarian cancer cells isolated from malignant ascites. Oncotarget. 2020;11:4570\u201381.","journal-title":"Oncotarget"},{"key":"1913_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-50794-w","volume":"9","author":"K Yamanoi","year":"2019","unstructured":"Yamanoi K, Baba T, Abiko K, Hamanishi J, Yamaguchi K, Murakami R, et al. Acquisition of a side population fraction augments malignant phenotype in ovarian cancer. Sci Rep. 2019;9:14215.","journal-title":"Sci Rep"},{"key":"1913_CR25","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/onc.2008.374","volume":"28","author":"T Baba","year":"2009","unstructured":"Baba T, Convery PA, Matsumura N, Whitaker RS, Kondoh E, Perry T, et al. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene. 2009;28:209\u201318.","journal-title":"Oncogene"},{"key":"1913_CR26","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.2119\/molmed.2012.00075","volume":"16","author":"H Jiangiang","year":"2012","unstructured":"Jiangiang H, Lin X, Liu Y, Gong W, Ma X, Yu Y, et al. Transformation of epithelial ovarian cancer stemlike cells into mesenchymal lineage via EMT results in cellular heterogeneity and supports tumor engraftment. Mol Med. 2012;16:1197\u2013208.","journal-title":"Mol Med"},{"key":"1913_CR27","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.2217\/fon-2018-0155","volume":"14","author":"C Liu","year":"2018","unstructured":"Liu C, Hu W, Li L-L, Wang YX, Zhou Q, Zhang F, et al. Roles of miR-200 family members in lung cancer: more than tumor suppressors. Future Oncol. 2018;14:2875\u201386.","journal-title":"Future Oncol"},{"key":"1913_CR28","doi-asserted-by":"publisher","first-page":"537","DOI":"10.7150\/thno.37423","volume":"10","author":"A Kotrbov\u00e1","year":"2020","unstructured":"Kotrbov\u00e1 A, Ovesn\u00e1 P, Gybel' T, Radaszkiewicz T, Bedna\u0159\u00edkov\u00e1 M, Hausnerov\u00e1 J, et al. WNT signaling inducing activity in ascites predicts poor outcome in ovarian cancer. Theranostics. 2020;10:537\u201352.","journal-title":"Theranostics"},{"key":"1913_CR29","first-page":"2245","volume":"44","author":"Q Han","year":"2019","unstructured":"Han Q, Huang B, Huang Z, Cai J, Gong L, Zhang Y, et al. Tumor cellfibroblast heterotypic aggregates in malignant ascites of patients with ovarian cancer. Int J Mol Med. 2019;44:2245\u201355.","journal-title":"Int J Mol Med"},{"key":"1913_CR30","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s12307-019-00227-z","volume":"12","author":"DR Alberto-Aguilar","year":"2019","unstructured":"Alberto-Aguilar DR, Hernandez-Ramirez VI, Osorio-Trujillo JC, Gallardo-Rincon D, Toledo-Leyva A, Talamas-Rohana P. Ascites from ovarian cancer induces novel fucosylated proteins. Cancer Microenviron. 2019;12:181\u201395.","journal-title":"Cancer Microenviron"},{"key":"1913_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-31097-y","volume":"8","author":"S Kim","year":"2018","unstructured":"Kim S, Kim S, Kim J, Kim B, Kim SI, Kim MA, et al. Evaluating tumor evolution via genomic profiling of individual tumor spheroids in a malignant ascites. Sci Rep. 2018;8:12724.","journal-title":"Sci Rep"},{"key":"1913_CR32","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/s41568-018-0056-x","volume":"18","author":"NK Lytle","year":"2018","unstructured":"Lytle NK, Barber AG, Reya T. Stem cell fate in cancer growth, progression and therapy resistance. Nat Rev Cancer. 2018;18:669\u201380.","journal-title":"Nat Rev Cancer"},{"key":"1913_CR33","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1158\/1535-7163.MCT-14-0579","volume":"14","author":"L Mo","year":"2015","unstructured":"Mo L, Bachelder RE, Kennedy M, Chen PH, Chi JT, Berchuck A, et al. Syngeneic murine ovarian cancer model reveals that ascites enriches for ovarian cancer stem-like cells expressing membrane GRP78. Mol Cancer Ther. 2015;14:747\u201356.","journal-title":"Mol Cancer Ther"},{"key":"1913_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8351","volume":"6","author":"B Aslan","year":"2015","unstructured":"Aslan B, Monroig P, Hsu M-C, Pena GA, Rodriguez-Aguayo C, Gonzalez-Villasana V, et al. The ZNF304-integrin axis protects against anoikis in cancer. Nat Commun. 2015;6:7351.","journal-title":"Nat Commun"},{"key":"1913_CR35","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.canlet.2019.04.034","volume":"457","author":"Y Hu","year":"2019","unstructured":"Hu Y, Qi C, Liu X, Zhang C, Gao J, Wu Y, et al. Malignant ascites-derived exosomes promote peritoneal tumor cell dissemination and reveal a distinct miRNA signature in advanced gastric cancer. Cancer Lett. 2019;457:142\u201350.","journal-title":"Cancer Lett"},{"key":"1913_CR36","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3390\/ijms20010137","volume":"20","author":"M Paku\u0142aaku\u0142a","year":"2019","unstructured":"Paku\u0142aaku\u0142a M, Miku\u0142a-Pietrasik J, Witucka A, Kostka-Jeziorny K, Uruski P, Moszy\u0144ski R, et al. The epithelial-mesenchymal transition initiated by malignant ascites underlies the transmesothelial invasion of ovarian cancer cells. Int J Mol Sci. 2019;20:137.","journal-title":"Int J Mol Sci"},{"key":"1913_CR37","first-page":"250","volume":"17","author":"Y-X Zhao","year":"2018","unstructured":"Zhao Y-X, Sun Y-Y, Huang A-L, Li XF, Huang C, Ma TT, et al. MicroRNA-200a induces apoptosis by targeting ZEB2 in alcoholic liver disease. Cell Cycle. 2018;17:250\u201362.","journal-title":"Cell Cycle"},{"key":"1913_CR38","first-page":"2009","volume":"12","author":"S Gu","year":"2019","unstructured":"Gu S, Chu C, Chen W, Ren H, Cao Y, Li X, et al. Prognostic value of epithelial-mesenchymal transition related genes: SLUG and QKI in breast cancer patients. Int J Clin Exp Pathol. 2019;12:2009\u201321.","journal-title":"Int J Clin Exp Pathol"},{"key":"1913_CR39","doi-asserted-by":"publisher","first-page":"199","DOI":"10.14740\/wjon1234","volume":"10","author":"RA Moussa","year":"2019","unstructured":"Moussa RA, Khalil EZI, Ali AI. Prognostic role of epithelial-mesenchymal transition markers \u201cE-cadherin, beta-catenin, ZEB1, ZEB2 and p63\u201d in bladder carcinoma. World J Oncol. 2019;10:199\u2013217.","journal-title":"World J Oncol"},{"key":"1913_CR40","doi-asserted-by":"publisher","first-page":"7387","DOI":"10.2147\/OTT.S218161","volume":"12","author":"Q Song","year":"2019","unstructured":"Song Q, Pang H, Qi L, Liang C, Wang T, Wang W, et al. Low microRNA-622 expression predicts poor prognosis and is associated with ZEB2 in glioma. Onco Targets Ther. 2019;12:7387\u201397.","journal-title":"Onco Targets Ther"},{"key":"1913_CR41","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1097\/IGC.0000000000001037","volume":"27","author":"Z Yan","year":"2017","unstructured":"Yan Z, Tian X, Wang R, Cheng X, Mi J, Xiong L, et al. Title prognosis significance of ZEB2 and TGF-beta1 as well as other clinical characteristics in epithelial ovarian cancer. Int J Gynecol Cancer. 2017;27:1343\u20139.","journal-title":"Int J Gynecol Cancer"},{"key":"1913_CR42","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1006\/gyno.2001.6284","volume":"82","author":"A Ahluwalia","year":"2001","unstructured":"Ahluwalia A, Hurteau JA, Bigsby RM, Nephew KP. DNA methylation in ovarian cancer. II. Expression of DNA methyltransferases in ovarian cancer cell lines and normal ovarian epithelial cells. Gynecol Oncol. 2001;82:299\u2013304.","journal-title":"Gynecol Oncol"},{"key":"1913_CR43","first-page":"891","volume":"53","author":"D Yu","year":"1993","unstructured":"Yu D, Wolf JK, Scanlon M, Price JE, Hung MC. Enhanced c-erbB-2\/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Cancer Res. 1993;53:891\u20138.","journal-title":"Cancer Res"},{"key":"1913_CR44","doi-asserted-by":"crossref","first-page":"e13251","DOI":"10.1111\/aji.13251","volume":"84","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, An J, Liu M, Li N, Wang W, Yao H, et al. Efficient isolation, culture, purification, and stem cell expression profiles of primary tumor cells derived from uterine cervical squamous cell carcinoma. Am J Reprod Immunol. 2020;84:e13251.","journal-title":"Am J Reprod Immunol"},{"key":"1913_CR45","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ccr.2012.12.020","volume":"23","author":"D Yang","year":"2013","unstructured":"Yang D, Sun Y, Hu L, Zheng H, Ji P, Pecot CV, et al. Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell. 2013;23:186\u201399.","journal-title":"Cancer Cell"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-021-01913-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-021-01913-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-021-01913-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,5]],"date-time":"2023-11-05T14:51:41Z","timestamp":1699195901000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-021-01913-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,1]]},"references-count":45,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2021,8,12]]}},"alternative-id":["1913"],"URL":"https:\/\/doi.org\/10.1038\/s41388-021-01913-3","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,1]]},"assertion":[{"value":"27 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}